Cargando…

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma

BACKGROUND: The 5-year cancer specific survival (CSS) for patients with muscle invasive urothelial carcinoma of the bladder (MIBC) treated with cystectomy alone is approximately 50%. Platinum based neoadjuvant chemotherapy (NAC) plus cystectomy results in a marginal 5-10% increase in 5-year CSS in M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baras, Alexander S., Gandhi, Nilay, Munari, Enrico, Faraj, Sheila, Shultz, Luciana, Marchionni, Luigi, Schoenberg, Mark, Hahn, Noah, Hoque, Mohammad, Berman, David, Bivalacqua, Trinity J., Netto, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521868/ https://www.ncbi.nlm.nih.gov/pubmed/26230923 http://dx.doi.org/10.1371/journal.pone.0131245

Ejemplares similares

Correction: Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma
por: Baras, Alexander S., et al.
Publicado: (2015)

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
por: Baras, Alexander S., et al.
Publicado: (2016)

An epigenetic marker panel for recurrence risk prediction of low grade papillary urothelial cell carcinoma (LGPUCC) and its potential use for surveillance after transurethral resection using urine
por: Maldonado, Leonel, et al.
Publicado: (2014)

Epigenetic inactivation of VGF associated with Urothelial Cell Carcinoma and its potential as a non-invasive biomarker using urine
por: Hayashi, Masamichi, et al.
Publicado: (2014)

Port Site Recurrence Following a Robotic Laparoscopic Radical Nephroureterectomy for Sarcomatoid Variant of Urothelial Carcinoma
por: Katz, Jonathan Elliott, et al.
Publicado: (2017)

Urothelial Carcinoma
por: Chow, Nan-Haw, et al.
Publicado: (2012)

Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture
por: Mi, Haoyang, et al.
Publicado: (2021)

Penile sarcomatoid urothelial carcinoma: A case report
por: Wang, Shirley, et al.
Publicado: (2021)

Impact of Sex on Response to Neoadjuvant Chemotherapy in Patients with Upper-tract Urothelial Cancer
por: D’Andrea, David, et al.
Publicado: (2020)

Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma
por: D’Andrea, David, et al.
Publicado: (2020)

CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer
por: Ooki, Akira, et al.
Publicado: (2018)

Do African American Patients Treated with Radical Cystectomy for Bladder Cancer have Worse Overall Survival? Accounting for Pathologic Staging and Patient Demographics Beyond Race Makes a Difference
por: Kaye, Deborah R., et al.
Publicado: (2016)

Regenerative Medicine for Erectile Dysfunction Following Radical Prostatectomy: Are we Ready?
por: Albersen, Maarten, et al.
Publicado: (2016)

Incidence and Distribution of UroSEEK Gene Panel in a Multi-institutional Cohort of Bladder Urothelial Carcinoma
por: Eich, Marie-Lisa, et al.
Publicado: (2019)

Surgical excision of a large, verrucous, scrotal mass in a patient with HSV-2 and HIV-1 co-infection
por: Luderowski, Eva, et al.
Publicado: (2018)

Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy
por: Uno, Kaname, et al.
Publicado: (2022)

Neoadjuvant chemotherapy for upper tract urothelial carcinoma
por: Kim, Do Kyung, et al.
Publicado: (2020)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer
por: Hirotsu, Yosuke, et al.
Publicado: (2020)

Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer
por: Milbar, Niv, et al.
Publicado: (2017)

Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer
por: Ball, Mark W., et al.
Publicado: (2017)

Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy
por: Ross, Ashley E., et al.
Publicado: (2017)

High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins
por: Zheng, Xiaoyong, et al.
Publicado: (2014)

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer
por: Zhang, Tian, et al.
Publicado: (2020)

The Use of Regenerative Medicine in the Management of Invasive Bladder Cancer
por: Hyndman, Matthew E., et al.
Publicado: (2012)

Current penile-rehabilitation strategies: Clinical evidence
por: Segal, Robert L., et al.
Publicado: (2013)

Evaluation and treatment of an unusual urachal mass: a case report
por: Cooper, John L, et al.
Publicado: (2015)

Innumerable Condyloma Acuminatum Tumors of the Bladder
por: Murray, Alexandra J., et al.
Publicado: (2017)

Evolving therapies for Peyronie’s disease: how can we work towards new drugs?
por: Milenkovic, Uros, et al.
Publicado: (2020)

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
por: Rosenberg, Jonathan E., et al.
Publicado: (2019)

Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression
por: Kashiwagi, Eiji, et al.
Publicado: (2018)

NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

In vivo Adenoviral Gene Transfer of CGRP and Related Peptides to the Rat and Mouse
por: Bivalacqua, Trinity, et al.
Publicado: (2001)

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine
por: Harshman, L C, et al.
Publicado: (2013)

Paclitaxel and carboplatin chemotherapy after platinum-based chemotherapy and pembrolizumab for metastatic urothelial carcinoma
por: Furubayashi, Nobuki, et al.
Publicado: (2021)

Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Hong, Joohyun, et al.
Publicado: (2022)

An Empirical vs Risk-Based Approach Algorithm to Intracavernosal Injection Therapy: A Prospective Study
por: Bernie, Helen Levey, et al.
Publicado: (2017)

Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy
por: Bellmunt, Joaquim, et al.
Publicado: (2016)

The expression of ERCC1 and BRCA1 predicts prognosis of platinum-based chemotherapy in urothelial cancer
por: Song, Wenhui, et al.
Publicado: (2016)

Author Correction: NICE’s rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good?
por: Gupta, Shilpa, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nooqsi3hccldor6punob7oplh8